Models of service delivery for optimizing a patient's first six months on antiretroviral therapy for HIV: an applied research agenda

Sydney Rosen, Anna Grimsrud, Peter Ehrenkranz, Ingrid Katz, Sydney Rosen, Anna Grimsrud, Peter Ehrenkranz, Ingrid Katz

Abstract

Differentiated models of service delivery (DSD models) for HIV treatment in sub-Saharan Africa were conceived as a way to manage rapidly expanding populations of experienced patients who are clinically "stable" on antiretroviral therapy (ART). Entry requirements for most models include at least six months on treatment and a suppressed viral load. These models thus systematically exclude newly-initiated patients, who instead experience the conventional model of care, which requires frequent, multiple clinic visits that impose costs on both providers and patients. In this open letter, we argue that the conventional model of care for the first six months on ART is no longer adequate. The highest rates of treatment discontinuation are in the first six-month period after treatment initiation. Newly initiating patients are generally healthier than in the past, with higher CD4 counts, and antiretroviral medications are better tolerated, with fewer side effects and substitutions, making extra clinic visits unnecessary. Improvements in the treatment initiation process, such as same-day initiation, have not been followed by innovations in the early treatment period. Finally, the advent of COVID-19 has made it riskier to require multiple clinic visits. Research to develop differentiated models of care for the first six-month period is needed. Priorities include estimating the minimum number and type of provider interactions and ART education needed, optimizing the timing of a patient's first viral load test, determining when lay providers can replace clinicians, ensuring that patients have sufficient but not burdensome access to support, and identifying ways to establish a habit of lifelong adherence.

Keywords: Africa; HIV; antiretroviral therapy; differentiated models; retention.

Conflict of interest statement

Competing interests: PE is an employee of the Bill & Melinda Gates Foundation, which partially funded the work reported here. The other authors declare that they have no competing interests.

Copyright: © 2020 Rosen S et al.

Figures

Figure 1.. Innovations in service delivery along…
Figure 1.. Innovations in service delivery along the HIV treatment cascade.
Adapted from under a CC BY 4.0 license.

References

    1. Grimsrud A, Bygrave H, Doherty M, et al. : Reimagining HIV service delivery: the role of differentiated care from prevention to suppression. J Int AIDS Soc. 2016;19(1):21484. 10.7448/IAS.19.1.21484
    1. Grimsrud A, Barnabas RV, Ehrenkranz P, et al. : Evidence for scale up: The differentiated care research agenda. J Int AIDS Soc. 2017;20(Suppl 4):22024. 10.7448/IAS.20.5.22024
    1. Long L, Kuchukhidze S, Pascoe S, et al. : Retention in care and viral suppression in differentiated service delivery models for HIV treatment in sub-Saharan Africa: a rapid systematic review. Preprints. 2020;1–21. 10.20944/preprints202005.0314.v1
    1. Kuchukhidze S, Long L, Pascoe S, et al. : Patient benefits and costs associated with differentiated models of service delivery for HIV treatment in Sub-Saharan Africa. AMBIT Report No. 01. Unpublished. Boston: Boston School of Public Health,2019.
    1. AMBIT Project: Eligibility criteria for differentiated service delivery models of hiv treatment in Sub-Saharan Africa. Unpublished. Boston: Boston School of Public Health,2020.
    1. Rosen S, Foxn MP, Gill CJ: Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4(10):e298. 10.1371/journal.pmed.0040298
    1. Fox MP, Rosen S: Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008–2013. J Acquir Immune Defic Syndr. 2015;69(1):98–108. 10.1097/QAI.0000000000000553
    1. Lilian RR, Rees K, McIntyre JA, et al. : Same-day antiretroviral therapy initiation for HIV-infected adults in South Africa: Analysis of routine data. PLoS One. 2020;15(1):e0227572. 10.1371/journal.pone.0227572
    1. Diseko L, Overmeyer R: South Africa DSD update. Johannesburg: CQUIN Annual Meeting, November 12,2019.
    1. Makurumidze R, Mutasa-Apollo T, Decroo T, et al. : Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe’s national antiretroviral therapy programme between 2012 and 2015. PLoS One. 2020;15(1):28–42. 10.1371/journal.pone.0222309
    1. Katz IT, Ryu AE, Onuegbu AG, et al. : Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013;16(3 Suppl 2):18640. 10.7448/IAS.16.3.18640
    1. Rueda S, Mitra S, Chen S, et al. : Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analyses. BMJ Open. 2016;6(7):e011453. 10.1136/bmjopen-2016-011453
    1. Pantelic M, Casale M, Cluver L, et al. : Multiple forms of discrimination and internalized stigma compromise retention in HIV care among adolescents: findings from a South African cohort. J Int AIDS Soc. 2020;23(5):e25488. 10.1002/jia2.25488
    1. IeDEA and COHERE Cohort Collaborations, . Anderegg N, Panayidou K, et al. : Global trends in CD4 cell count at the start of antiretroviral therapy: collaborative study of treatment programs. Clin Infect Dis. 2018;66(6):893–903. 10.1093/cid/cix915
    1. Ford N, Meintjes G, Calmy A, et al. : Managing advanced HIV disease in a public health approach. Clin Infect Dis. 2018;66(Suppl_2):S106–S110. 10.1093/cid/cix1139
    1. Yonga P, Kalya S, Lynen L, et al. : Temporary disengagement and re-engagement in human immunodeficiency virus care in a rural county serving pastoralist communities in Kenya: A retrospective cohort study. Int Health. 2019;12(2):95–100. 10.1093/inthealth/ihz049
    1. Maskew M, Brennan AT, Fox MP, et al. : A structured algorithm for same-day art initiation: SLATE II trial primary outcomes. Abstract 1070, CROI 2020, March 8-11,2020.
    1. Brennan AT, Bor J, Davies MA, et al. : Medication side effects and retention in HIV treatment: A regression discontinuity study of tenofovir implementation in South Africa and Zambia. Am J Epidemiol. 2018;187(9):1990–2001. 10.1093/aje/kwy093
    1. World Health Organization: Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization,2017.
    1. Siedner MJ, Lankowski A, Haberer JE, et al. : Rethinking the ‘“Pre”’ in Pre-Therapy Counseling: No Benefit of Additional Visits Prior to Therapy on Adherence or Viremia in Ugandans Initiating ARVs. PLoS One. 2012;7(6):e39894. 10.1371/journal.pone.0039894
    1. Ndaliso C: Thousands of HIV-positive patients miss hospital appointments amid coronavirus lockdown. IOL. 30 Apr 2020.
    1. Molelekwa T: Barriers to ARV access during lockdown. Health-e News. 2020.
    1. Fox MP, Rosen S: A new cascade of HIV care for the era of “treat all”. PLoS Medicine. 2017;14:e1002268 10.1371/journal.pmed.1002268
    1. Mody A, Eshun-Wilson I, Sikombe K, et al. : Longitudinal engagement trajectories and risk of death among new ART starters in Zambia: A group-based multi-trajectory analysis. PLoS Med. 2019;16(10):e1002959. 10.1371/journal.pmed.1002959
    1. Ahmed S, Autrey J, Katz IT, et al. : Why do people living with HIV not initiate treatment? A systematic review of qualitative evidence from low- and middle-income countries. Soc Sci Med. 2018;213:72–84. 10.1016/j.socscimed.2018.05.048
    1. Kerschberger B, Boulle AM, Kranzer K, et al. : Superior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapy. J Int AIDS Soc. 2015;18(1):20092. 10.7448/IAS.18.1.20092
    1. Venter WDF, Moorhouse M, Sokhela S, et al. : Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–815. 10.1056/NEJMoa1902824
    1. Yah CS, Tambo E, Khayeka-Wandabwa C, et al. : Impact of telemonitoring approaches on integrated HIV and TB diagnosis and treatment interventions in sub-Saharan Africa: a scoping review. Heal Promot Perspect. 2017;7(2):60–65. 10.15171/hpp.2017.12
    1. Knettel BA, Mulawa MI, Knippler ET, et al. : Women’s perspectives on ImpACT: a coping intervention to address sexual trauma and improve HIV care engagement in Cape Town, South Africa. AIDS Care. 2019;31(11):1389–1396. 10.1080/09540121.2019.1587368
    1. Katz I, Bogart L, Courtney I, et al. : The treatment ambassador program: a pilot randomized controlled trial for people living with HIV in South Africa who delay or discontinue treatment. 13th International Conference on HIV Treatment and Prevention Adherence, Miami Beach, FL: June 8-10.2018.
    1. Bengtson AM, Chibwesha CJ, Westreich D, et al. : A risk score to identify hiv-infected women most likely to become lost to follow-up in the postpartum period. AIDS Care. 2016;28(8):1035–1045. 10.1080/09540121.2016.1144869

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe